{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:43Z","timestamp":1792130743321,"version":"4.4.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.drudis.2010.10.009","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T04:56:50Z","timestamp":1288069010000},"page":"1058-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Heparin\/heparan sulphate-based drugs"],"prefix":"10.1016","volume":"15","author":[{"given":"Neha S.","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo L.","family":"Mancera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2010.10.009_bib0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1163\/156856001300248443","article-title":"Role of glycosaminoglycans in inflammation","volume":"9","author":"Lever","year":"2001","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.drudis.2010.10.009_bib0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nri1918","article-title":"The role of heparan sulphate in inflammation","volume":"6","author":"Parish","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ni0905-861","article-title":"Heparan sulfate and inflammation","volume":"6","author":"Parish","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0020","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0196-9781(02)00068-2","article-title":"Glycosaminoglycans and \u03b2-amyloid, prion and tau peptides in neurodegenerative diseases","volume":"23","author":"D\u00edaz-Nido","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.drudis.2010.10.009_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI200113738","article-title":"Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena","volume":"108","author":"Iozzo","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.10.009_bib0030","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1172\/JCI119377","article-title":"Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?","volume":"99","author":"Rosenberg","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.10.009_bib0035","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1535-7163.MCT-06-0082","article-title":"Therapeutic value of glycosaminoglycans in cancer","volume":"5","author":"Yip","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2010.10.009_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/iai.65.1.1-8.1997","article-title":"Microbial adherence to and invasion through proteoglycans","volume":"65","author":"Rostand","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.drudis.2010.10.009_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02456129","article-title":"Protein\u2013glycosaminoglycan interactions: infectiological aspects","volume":"184","author":"Sawitzky","year":"1996","journal-title":"Med. Microbiol. Immunol. (Berl.)"},{"key":"10.1016\/j.drudis.2010.10.009_bib0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1099\/00222615-48-3-223","article-title":"Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity","volume":"48","author":"Wadstrom","year":"1999","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1747-0285.2008.00741.x","article-title":"The structure of glycosaminoglycans and their interactions with proteins","volume":"72","author":"Gandhi","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.drudis.2010.10.009_bib0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2010.10.009_bib0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10409230701751611","article-title":"Glycan antagonists and inhibitors: a fount for drug discovery","volume":"42","author":"Brown","year":"2007","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0070","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd1521","article-title":"Glycomics: a pathway to a class of new and improved therapeutics","volume":"3","author":"Shriver","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2010.10.009_bib0075","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1211\/0022357023619","article-title":"Carbohydrate-based therapeutics","volume":"56","author":"Osborn","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0080","first-page":"521","article-title":"Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome","volume":"8","author":"Gesslbauer","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.drudis.2010.10.009_bib0085","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2174\/092986706777452470","article-title":"Therapeutic applications of glycosaminoglycans","volume":"13","author":"Volpi","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1160\/TH07-04-0310","article-title":"Heparan sulfate\u2013protein interactions: a concept for drug design?","volume":"98","author":"Lindahl","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/1389557033487755","article-title":"The potential of the molecular diversity of heparin and heparan sulfate for drug development","volume":"3","author":"Fugedi","year":"2003","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.10.009_bib0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-009-0392-5","article-title":"Newer anticoagulants in 2009","volume":"29","author":"Samama","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2010.10.009_bib0110","first-page":"119","article-title":"Emerging anticoagulants: mechanism of action and future potential","volume":"52","author":"Klement","year":"2006","journal-title":"Vnitr. Lek."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2010.10.009_bib0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2002-32313","article-title":"Selective inhibition of coagulation factors: advances in antithrombotic therapy","volume":"28","author":"Bauer","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1359-6446(05)03457-4","article-title":"Synthetic heparin derivatives as new anticoagulant drugs","volume":"10","author":"De Kort","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2010.10.009_bib0125","first-page":"51","article-title":"Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles","volume":"28","author":"Alban","year":"2008","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.drudis.2010.10.009_bib0130","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1021\/bi00344a063","article-title":"Contribution of monosaccharide residues in heparin binding to antithrombin III","volume":"24","author":"Atha","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2010.10.009_bib0135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.78.2.829","article-title":"Multiple functional domains of the heparin molecule","volume":"78","author":"Oosta","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2010.10.009_bib0140","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1002\/anie.200300640","article-title":"A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew","volume":"43","author":"Petitou","year":"2004","journal-title":"Chem. Int. Ed. Engl."},{"key":"10.1016\/j.drudis.2010.10.009_bib0145","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/anie.199316713","article-title":"The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics","volume":"32","author":"Van Boeckel","year":"1993","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.drudis.2010.10.009_bib0150","doi-asserted-by":"crossref","first-page":"15941","DOI":"10.1074\/jbc.M212319200","article-title":"Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation","volume":"278","author":"Jairajpuri","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1160\/TH09-01-0063","article-title":"From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile","volume":"102","author":"Petitou","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0160","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/1381612033453929","article-title":"Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties","volume":"9","author":"Avci","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2010.10.009_bib0165","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/14656566.5.6.1373","article-title":"Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy","volume":"5","author":"Turpie","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2010.10.009_bib0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543780903020308","article-title":"Discontinued drugs in 2008: cardiovascular drugs","volume":"18","author":"Xu-song","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0175","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2010.10.009_bib0180","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1021\/bi6024929","article-title":"High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions","volume":"46","author":"Hjelm","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2010.10.009_bib0185","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1021\/bi981426h","article-title":"Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites","volume":"37","author":"Desai","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2010.10.009_bib0190","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1074\/jbc.273.13.7478","article-title":"Mechanism of heparin activation of antithrombin: role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin","volume":"273","author":"Desai","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0195","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0968-0896(00)82078-7","article-title":"Feasible synthesis and biological properties of six \u2018non-glycosamino\u2019 glycan analogues of the antithrombin III binding heparin pentasaccharide","volume":"2","author":"Westerduin","year":"1994","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0200","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0960-894X(00)80584-3","article-title":"Biologically active heparin-like fragments with a \u201cnon-glycosamino\u201dglycan structure. Part 2: a tetra-o-methylated pentasaccharide with high affinity for antithrombin III","volume":"2","author":"Basten","year":"1992","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2010.10.009_bib0205","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1073\/pnas.94.26.14683","article-title":"The anticoagulant activation of antithrombin by heparin","volume":"94","author":"Jin","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2010.10.009_bib0210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-2836(02)01382-7","article-title":"Structure of \u03b2-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity","volume":"326","author":"McCoy","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0215","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.17.5.773","article-title":"Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders","volume":"17","author":"Prandoni","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0220","first-page":"490","article-title":"A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers","author":"Faaij","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0225","first-page":"853","article-title":"A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers","author":"Faaij","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0230","first-page":"1028","article-title":"Idraparinux sodium","volume":"7","author":"Ma","year":"2004","journal-title":"IDrugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0235","first-page":"301","article-title":"A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation","volume":"100","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2010.10.009_bib0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation","volume":"2","author":"Buller","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0245","first-page":"540","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation","volume":"2","author":"Minar","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0250","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2010.10.009_bib0255","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2010.10.009_bib0260","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-008-0463-0","article-title":"Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials","volume":"64","author":"Harenberg","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0265","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1538-7836.2008.02943.x","article-title":"Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials","volume":"6","author":"Harenberg","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2010.10.009_bib0270","first-page":"21","article-title":"The anticoagulant Idraparinux: is the extensive half life of 60 days the cause of bleeding complications","volume":"68","author":"Harenberg","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0275","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0280","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1538-7836.2009.03298.x","article-title":"The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials","volume":"7","author":"Veyrat-Follet","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0285","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2010.10.009_bib0290","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1160\/TH09-08-0555","article-title":"Development of idraparinux and idrabiotaparinux for anticoagulant therapy","volume":"102","author":"Harenberg","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0295","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1538-7836.2008.03089.x","article-title":"Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy","volume":"6","author":"Savi","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0300","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0029-1234147","article-title":"New anticoagulants for atrial fibrillation","volume":"35","author":"Sobieraj-Teague","year":"2009","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0305","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2009.03447.x","article-title":"Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026","volume":"7","author":"Viskov","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"15 Suppl.","key":"10.1016\/j.drudis.2010.10.009_bib0310","doi-asserted-by":"crossref","first-page":"14653","DOI":"10.1200\/jco.2008.26.15_suppl.14653","article-title":"AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis","volume":"26","author":"Hoppensteadt","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0315","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1538-7836.2009.03301.x","article-title":"AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery \u2013 TREK: a dose-ranging study","volume":"7","author":"Lassen","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0320","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ahj.2009.08.020","article-title":"Design and rationale of the evaluation of M118 in percutaneous coronary intervention (EMINENCE) trial","volume":"158","author":"Melloni","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2010.10.009_bib0325","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1160\/TH09-02-0105","article-title":"M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes","volume":"102","author":"Kishimoto","year":"2009","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2010.10.009_bib0330","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.toxlet.2009.06.364","article-title":"Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5\/6 nephrectomized uremic rats","volume":"189","author":"Draganov","year":"2009","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.drudis.2010.10.009_bib0335","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11239-009-0360-0","article-title":"A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation","volume":"28","author":"Volovyk","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2010.10.009_bib0340","first-page":"379A","article-title":"A novel, rationally engineered heparin (M118) prevents thrombosis more effectively than unfractionated heparin in a canine model of deep arterial injury","volume":"49","author":"Fier","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0345","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11239-009-0340-4","article-title":"M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice","volume":"28","author":"Chakrabarti","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2010.10.009_bib0350","first-page":"73","article-title":"Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects","volume":"49","author":"Fier","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0355","series-title":"Proceedings of the XXII Congress of the International Society of Thrombosis and Haemostasis","article-title":"Anticoagulant activities of EP42675 \u2013 synthetic direct inhibitor and indirect factor Xa inhibitor","author":"Bal Dit Sollier","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0360","series-title":"Antithrombotic Dual Inhibitors Comprising a Biotin Residue","author":"De Kort","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0365","series-title":"Proceedings of the XII congress of the International Society of Thrombosis and Haemostasis","article-title":"Pharmacokinetics and pharmacodynamics of EP42675 a new synthetic anticoagulant with a dual mechanism of action","author":"Bal Dit Sollier","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0370","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157016309789869001","article-title":"Therapeutic use of heparin beyond anticoagulation","volume":"6","author":"Ludwig","year":"2009","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0375","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2010.10.009_bib0380","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins. Experimental evidence","volume":"125","author":"Borsig","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0707182","article-title":"Heparanase: a target for drug discovery in cancer and inflammation","volume":"151","author":"McKenzie","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0390","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI13662","article-title":"Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis","volume":"108","author":"Vlodavsky","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.10.009_bib0395","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2174\/092986706777935230","article-title":"Development of heparanase inhibitors for anti-cancer therapy","volume":"13","author":"Miao","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0400","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1517\/13543784.17.11.1769","article-title":"PI-88: a novel inhibitor of angiogenesis","volume":"17","author":"Kudchadkar","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0405","first-page":"38","article-title":"The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug","volume":"13","author":"Ferro","year":"2003","journal-title":"Australas. Biotechnol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0410","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0049-3848(01)00314-0","article-title":"Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides","volume":"103","author":"Wall","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0415","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/1078-0432.CCR-05-2423","article-title":"A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors","volume":"12","author":"Basche","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0420","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdf117","article-title":"Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia","volume":"13","author":"Rosenthal","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-008-0712-z","article-title":"A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies","volume":"63","author":"Chow","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 18","key":"10.1016\/j.drudis.2010.10.009_bib0430","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1200\/jco.2007.25.18_suppl.8532","article-title":"Final results of a phase I study of daily PI-88 as a single agent and in combination with dacarbazine (D) in patients with metastatic melanoma","volume":"25","author":"Millward","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0435","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/annonc\/mdp524","article-title":"Multicentre phase I\/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer","volume":"21","author":"Khasraw","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-007-9080-5","article-title":"A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma","volume":"26","author":"Lewis","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0445","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1021\/jm050618p","article-title":"Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88)","volume":"48","author":"Karoli","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0450","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-2007-982088","article-title":"PI-88 and novel heparan sulfate mimetics inhibit angiogenesis","volume":"33","author":"Ferro","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0455","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-009-9245-5","article-title":"The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy","volume":"28","author":"Dredge","year":"2009","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0460","series-title":"Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Mol. Cancer Ther. (Meeting Abstract Supplement)","article-title":"The dual angiogenesis\/heparanase inhibitor PG545, but not the tyrosine kinase inhibitor sorafenib, inhibits spontaneous metastasis in models of breast and lung cancer","author":"Bytheway","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0465","series-title":"Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Mol. Cancer Ther. (Meeting Abstract Supplement)","article-title":"The dual angiogenesis\/heparanase inhibitor PG545 inhibits solid tumor progression in models of breast, prostate and liver cancer: a comparative assessment of once versus twice weekly administration schedules","author":"Hammond","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0470","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1474-4422(03)00484-8","article-title":"Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders","volume":"2","author":"van Horssen","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0475","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1432-1327.1999.00957.x","article-title":"Interactions of Alzheimer amyloid-\u03b2 peptides with glycosaminoglycans","volume":"266","author":"McLaurin","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0480","first-page":"1389","article-title":"Binding of heparan sulfate glycosaminoglycan to [beta]-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds","volume":"5","author":"Leveugle","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.drudis.2010.10.009_bib0485","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0295-143","article-title":"Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease","volume":"1","author":"Kisilevsky","year":"1995","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2010.10.009_bib0490","first-page":"S2","article-title":"Functional GAG mimetics as an approach for the treatment of amyloid diseases","volume":"1","author":"Tremblay","year":"2005","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.drudis.2010.10.009_bib0495","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/156720507781788882","article-title":"Alzhemed: a potential treatment for Alzheimers disease","volume":"4","author":"Aisen","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0500","first-page":"95","article-title":"NC-531 (Neurochem)","volume":"5","author":"Geerts","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2010.10.009_bib0505","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dot.2006.42.5.973584","article-title":"Tramiprosate","volume":"42","author":"Wright","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.drudis.2010.10.009_bib0510","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2010.10.009_bib0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-2-17","article-title":"Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau","volume":"2","author":"Santa-Maria","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.drudis.2010.10.009_bib0520","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","article-title":"A Phase II study targeting amyloid-\u03b2 with 3APS in mild-to-moderate Alzheimer disease","volume":"67","author":"Aisen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2010.10.009_bib0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.drudis.2010.10.009_bib0530","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12603-009-0047-4","article-title":"Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the Alzhemed\u2122 (Tramiprosate) experience","volume":"13","author":"Saumier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.drudis.2010.10.009_bib0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/msj.20165","article-title":"Current treatment and recent clinical research in Alzheimer's disease","volume":"77","author":"Neugroschl","year":"2010","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.drudis.2010.10.009_bib0540","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1358\/dof.2006.031.07.1012786","article-title":"Eprodisate sodium","volume":"31","author":"Revill","year":"2006","journal-title":"Drugs Future"},{"key":"10.1016\/j.drudis.2010.10.009_bib0545","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1074\/jbc.274.11.7172","article-title":"The heparin\/heparan sulfate-binding site on apo-serum Amyloid A","volume":"274","author":"Ancsin","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0550","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/1568013033483294","article-title":"Proteoglycans and amyloidogenic proteins in peripheral amyloidosis","volume":"3","author":"Gervais","year":"2003","journal-title":"Curr. Med. Chem. Immunol. Endocr. Metab. Agents"},{"key":"10.1016\/j.drudis.2010.10.009_bib0555","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/13506120009146820","article-title":"The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000","volume":"7","author":"Kisilevsky","year":"2000","journal-title":"Amyloid"},{"key":"10.1016\/j.drudis.2010.10.009_bib0560","unstructured":"Clinicaltrials.gov. (2002) A phase II\/III study of the safety and efficacy of NC-503 in patients suffering from secondary (AA) amyloidosis (NCT00035334)."},{"key":"10.1016\/j.drudis.2010.10.009_bib0565","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for the treatment of renal disease in AA amyloidosis","volume":"356","author":"Dember","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2010.10.009_bib0570","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1517\/14656566.9.12.2175","article-title":"Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?","volume":"9","author":"Manenti","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2010.10.009_bib0575","series-title":"BELLUS Health Ends NC-503 Diabetes Development Program following Results","author":"Bellini","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0580","series-title":"Proceedings of the Lysosomal Disease Network WORLD Symposium, vol. 99","first-page":"S12","article-title":"Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses","author":"Brown","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0585","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.matbio.2010.04.003","article-title":"Heparin-derived heparan sulfate mimics to modulate heparan sulfate\u2013protein interaction in inflammation and cancer","volume":"29","author":"Casu","year":"2010","journal-title":"Matrix Biol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0590","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2174\/138161207781039742","article-title":"Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate","volume":"13","author":"Vlodavsky","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2010.10.009_bib0595","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1160\/TH06-05-0289","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2010.10.009_bib0600","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s11095-009-9989-9","article-title":"Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells","volume":"26","author":"Lee","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0605","series-title":"Proceedings of the 67th Harden Conference","article-title":"Heparan sulfate mimetics as anticancer small-glyco drugs","author":"Cabannes","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0610","series-title":"Proceedings of the AACR meeting","article-title":"Antitumor activity of EP80061, a small-glyco drug in preclinical studies","author":"Serina","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0615","series-title":"M402 \u2013 A Novel Heparan Sulfate Proteoglycan Mimetic Targeting Tumor\u2013Host Interactions","author":"Zhou","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0620","series-title":"Proceedings of the 100th Annual Meeting of American Association for Cancer Research (AACR)","article-title":"M-ONC 402-a non anticoagulant low molecular weight heparin inhibits tumor metastasis","author":"Zhou","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0625","series-title":"Proceedings of the100th Annual Meeting of American Association for Cancer Research (AACR)","article-title":"M-ONC 402, A novel non-anticoagulant heparin, inhibits P-Selectin function and metastatic seeding of tumor cells in mice","author":"Chu","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0630","series-title":"M402, A Novel Heparan Sulfate Mimetic, Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer","author":"Lolkema","year":"2010"},{"key":"10.1016\/j.drudis.2010.10.009_bib0635","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0003-4509(06)75306-8","article-title":"Regenerating agents (RGTAs): a new therapeutic approach","volume":"64","author":"Barritault","year":"2006","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.drudis.2010.10.009_bib0640","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jcp.1041500126","article-title":"Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF","volume":"150","author":"Tardieu","year":"1992","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0645","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H","article-title":"Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage","volume":"31","author":"Meddahi","year":"1996","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0650","doi-asserted-by":"crossref","first-page":"32792","DOI":"10.1074\/jbc.M504492200","article-title":"A synthetic glycosaminoglycan mimetic minds vascular endothelial growth factor and modulates angiogenesis","volume":"280","author":"Rouet","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0655","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0141-8130(95)01074-2","article-title":"FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives","volume":"18","author":"Meddahi","year":"1996","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0660","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0300-9084(96)88185-5","article-title":"Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation","volume":"77","author":"Meddahi","year":"1995","journal-title":"Biochimie"},{"key":"10.1016\/j.drudis.2010.10.009_bib0665","doi-asserted-by":"crossref","first-page":"29383","DOI":"10.1074\/jbc.M000837200","article-title":"Human plasmin enzymatic activity is inhibited by chemically modified dextrans","volume":"275","author":"Ledoux","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.10.009_bib0670","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jbm.a.30723","article-title":"Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro","volume":"78","author":"Rouet","year":"2006","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.drudis.2010.10.009_bib0675","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jbm.a.32124","article-title":"Matrix therapy in regenerative medicine, a new approach to chronic wound healing","volume":"90","author":"Barbier-Chassefi\u00e8re","year":"2009","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.drudis.2010.10.009_bib0680","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0344-0338(11)80997-0","article-title":"New approaches to tissue regeneration and repair","volume":"190","author":"Meddahi","year":"1994","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.drudis.2010.10.009_bib0685","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001665-199601000-00007","article-title":"Modulation of cranial bone healing with a heparin-like dextran derivative","volume":"7","author":"Albo","year":"1996","journal-title":"J. Craniofac. Surg."},{"key":"10.1016\/j.drudis.2010.10.009_bib0690","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/8756-3282(95)00402-5","article-title":"Heparan-like molecules induce the repair of skull defects","volume":"17","author":"Blanquaert","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2010.10.009_bib0695","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1096\/fj.99-0565fje","article-title":"New agents for the treatment of infarcted myocardium","volume":"14","author":"Yamauchi","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2010.10.009_bib0700","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jbm.1293","article-title":"Heparin-like polymer improved healing of gastric and colic ulceration","volume":"60","author":"Meddahi","year":"2002","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0705","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1096\/fj.02-0708com","article-title":"A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers","volume":"17","author":"Escartin","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2010.10.009_bib0710","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbm.10192","article-title":"Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro","volume":"62","author":"Papy-Garcia","year":"2002","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0715","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbrc.2003.10.150","article-title":"Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis","volume":"312","author":"Schonberger","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2010.10.009_bib0720","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1099\/vir.0.19073-0","article-title":"A novel generation of heparan sulfate mimetics for the treatment of prion diseases","volume":"84","author":"Adjou","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0725","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1242\/jcs.01607","article-title":"A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis","volume":"118","author":"Barbosa","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drudis.2010.10.009_bib0730","first-page":"1037","article-title":"Effect of a substituted dextran on reinnervation during regeneration of adult rat skeletal muscle","volume":"318","author":"Aamiri","year":"1995","journal-title":"C. R. Acad. Sci. III. Sci. Vie"},{"key":"10.1016\/j.drudis.2010.10.009_bib0735","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1021\/ma048485p","article-title":"Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics","volume":"38","author":"Papy-Garcia","year":"2005","journal-title":"Macromolecules"},{"key":"10.1016\/j.drudis.2010.10.009_bib0740","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.matbio.2010.02.002","article-title":"Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts","volume":"29","author":"Martelly","year":"2010","journal-title":"Matrix Biol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0745","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3171\/JNS\/2008\/109\/11\/0967","article-title":"Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats","volume":"109","author":"Zuijdendorp","year":"2008","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drudis.2010.10.009_bib0750","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jbm.a.30874","article-title":"RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin","volume":"80","author":"Garcia-Filipe","year":"2007","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.drudis.2010.10.009_bib0755","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1524-475X.2009.00548.x","article-title":"Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120","volume":"17","author":"Tong","year":"2009","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.drudis.2010.10.009_bib0760","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jbm.10283","article-title":"Pharmacological studies of RGTA11, a heparan sulfate mimetic polymer, efficient on muscle regeneration","volume":"62","author":"Meddahi","year":"2002","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.drudis.2010.10.009_bib0765","first-page":"465","article-title":"Pilot study of a new matrix therapy agent (RGTA OTR4120\u00ae) in treatment-resistant corneal ulcers and corneal dystrophy","volume":"31","author":"Chebbi","year":"2008","journal-title":"J. Fr. Opthalmol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0770","series-title":"In Vitro Characterization of the Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives","author":"Jeske","year":"2007"},{"key":"10.1016\/j.drudis.2010.10.009_bib0775","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1096\/fasebj.23.1_supplement.569.6","article-title":"Neutralization of hemorrhagic and antithrombotic activities of heparins by a novel salicylamide derivative","volume":"23","author":"Kuziej","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2010.10.009_bib0780","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1096\/fasebj.22.1_supplement.1118.7","article-title":"Neutralization of the anticoagulant and anti-Xa effects of fondaparinux and idraparinux by a novel synthetic antagonist. Pharmacologic implications","volume":"22","author":"Fareed","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2010.10.009_bib0785","series-title":"Novel Antagonists for Low Molecular Weight Heparin and Heparin-like Drugs","author":"Jeske","year":"2009"},{"key":"10.1016\/j.drudis.2010.10.009_bib0790","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ddtec.2004.11.017","article-title":"The synthesis of well-defined heparin and heparan sulfate fragments","volume":"1","author":"Cod\u00e9e","year":"2004","journal-title":"Drug Discov Today: Technol."},{"key":"10.1016\/j.drudis.2010.10.009_bib0795","first-page":"S12","article-title":"Small molecule inhibitors of glycosaminoglycan biosynthesisas substrate optimization therapy for the mucopolysaccharidoses","volume":"99","author":"Brown","year":"2010","journal-title":"Mol. Genet. Metab."}],"updated-by":[{"DOI":"10.1016\/j.drudis.2011.02.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000}}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644610007798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644610007798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:07:52Z","timestamp":1761221272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644610007798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":159,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1359644610007798"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2010.10.009","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin\/heparan sulphate-based drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2010.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}